Reprocell Inc operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Reprocell Inc with three other
pharmaceutical manufacturers in Asia:
Nutraplus India Ltd
sales of 915.42 million Indian Rupees [US$14.15 million]
Natural Capsules Limited
(536.43 million Indian Rupees [US$8.29 million]
Ngl Fine Chem Ltd
based in India
(1.00 billion Indian Rupees [US$15.48 million]
During the year ended March of 2017, sales at
Reprocell Inc were ¥1.26 billion (US$11.24 million).
increase of 18.0%
versus 2016, when the company's sales were ¥1.07 billion.
This was the fifth consecutive year of sales increases at Reprocell Inc
(and since 2012, sales have increased a total of 297%).
Sales of Ips Cell Business saw an increase
20.7% in 2017, from
¥999.93 million to ¥1.21 billion.
Not all segments of Reprocell Inc experienced an increase in sales in 2017:
sales of Clinical Testing Business fell 23.3% to ¥50.95 million.